Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.

<h4>Background</h4>NVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.<h4>Methods and findings</h4>The phase 2 component of our randomize...

Full description

Bibliographic Details
Main Authors: Neil Formica, Raburn Mallory, Gary Albert, Michelle Robinson, Joyce S Plested, Iksung Cho, Andreana Robertson, Filip Dubovsky, Gregory M Glenn, 2019nCoV-101 Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-10-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.1003769

Internet

https://doi.org/10.1371/journal.pmed.1003769

Similar Items